IN8bio to Present at Cantor Oncology & HemOnc Conference

Rhea-AI Summary

IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will speak at the “Cell Therapy in Solid Tumors” panel during the Cantor Oncology & HemOnc Conference on September 28, 2022, at 1:45 p.m. ET. IN8bio is focused on developing innovative gamma-delta T cell therapies for solid and liquid tumors through its DeltEx platform. The company is conducting Phase 1 clinical trials for INB-200, targeting newly diagnosed glioblastoma, and INB-100 for leukemia patients undergoing stem cell transplantation, alongside its preclinical programs.

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced that William Ho, IN8bio’s Chief Executive Officer, will be a speaker on the “Cell Therapy in Solid Tumors” panel at the Cantor Oncology & HemOnc Conference. The panel will take place at 1:45 p.m. ET on September 28, 2022.

About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop cell therapies that synergize with chemotherapy to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit www.IN8bio.com.

Company Contact:
IN8bio, Inc.
Patrick McCall
+ 1 646.600.6GDT (6438)
info@IN8bio.com

Investors & Media Contact:
Argot Partners
IN8bio@argotpartners.com

FAQ

What is the date and time of William Ho's presentation at the Cantor Oncology & HemOnc Conference?

William Ho's presentation is scheduled for September 28, 2022, at 1:45 p.m. ET.

What is IN8bio's main focus in biopharmaceuticals?

IN8bio focuses on discovering and developing gamma-delta T cell therapies for treating solid and liquid tumors.

What are the key trials currently being conducted by IN8bio?

IN8bio is conducting Phase 1 clinical trials for INB-200 for glioblastoma and INB-100 for leukemia patients.

What platform does IN8bio use for its T cell therapies?

IN8bio utilizes the DeltEx platform to develop its gamma-delta T cell therapies.

What types of cancer are targeted by IN8bio's therapies?

IN8bio targets solid tumors and leukemia through its gamma-delta T cell therapies.